Therapeutics News and Research

RSS

Alnylam to defend against Tekmira complaint

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, is reporting the filing of a complaint by Tekmira Pharmaceuticals Corporation in the Business Litigation Session (BLS) of the Massachusetts Superior Court. The complaint alleges misappropriation and misuse of information, amongst other allegations.

18 Mar 2011

Scientists receive £5million EU grant to identify gene targets for kidney cancer treatment

An international consortium led by scientists from the Cancer Research UK London Research Institute, The Royal Marsden Hospital and the Technical University of Denmark has been granted nearly £5million by the European Union to identify gene targets for personalised treatment for kidney cancer patients.

18 Mar 2011

ACT initiates enrollment in TEMPASURE cardiac ablation catheter CE Mark clinical trial

Advanced Cardiac Therapeutics, Inc., a developer of innovative temperature-sensing cardiac ablation systems, today announced that the first patients have been enrolled in a first-in-man CE Mark clinical trial of the safety and performance of the company's TEMPASURE™ cardiac ablation catheter. The TEMPASURE system is the world's first RF cardiac ablation catheter to offer both saline irrigation and temperature-sensing technology.

17 Mar 2011

Astellas to acquire all Maxygen's equity interests in Perseid for $76.0 million

Maxygen, Inc. today announced that Astellas Pharma Inc. has exercised its option to purchase all of Maxygen's equity interests in Perseid Therapeutics LLC at the current exercise price of $76.0 million.

17 Mar 2011

Inovio signs agreement with OncoSec to sell non-DNA cancer vaccine technology

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has signed an agreement with OncoSec Medical Inc. providing for the sale to OncoSec of certain non-DNA vaccine technology and intellectual property relating to electroporation technology useful for electrochemical and cytokine based immune therapies for treating solid tumors.

17 Mar 2011

PsiOxus commences MT-102 Phase II study for treatment of cancer- and age-related wasting

PsiOxus Therapeutics, Ltd. announced initiation of a Phase II study of MT-102, a small molecule therapeutic for the treatment of cancer- and age-related wasting. MT-102 is being developed to reverse the effects of cachexia, a wasting disease that accompanies cancer, heart failure, COPD, renal failure, cirrhosis and rheumatoid arthritis, and that is associated with significant morbidity and mortality.

17 Mar 2011

Researchers update 'Hallmarks of Cancer' seminal review

Renowned cancer researchers Robert Weinberg, a Founding Member of Whitehead Institute, and Douglas Hanahan, Director of the Swiss Institute for Experimental Cancer Research have updated their seminal review, "Hallmarks of Cancer," which has influenced the study of cancer and the development of therapeutics for more than a decade.

17 Mar 2011

HGSI, FivePrime enter agreement to develop, commercialize FP-1039 for multiple cancers

Human Genome Sciences, Inc. and FivePrime Therapeutics, Inc. announced today that they have entered into an agreement to develop and commercialize FivePrime's FP-1039 product for multiple cancers.

17 Mar 2011

Pharmaron signs agreement to provide Isis with nucleoside phosphoramidites up to 100 kg

Pharmaron has signed an agreement to provide Isis Pharmaceuticals, Inc. with nucleoside phosphoramidites at quantities up to 100 kg. Nucleoside phosphoramidites are fundamental building blocks in the production of antisense therapeutics.

17 Mar 2011

MorphoSys inks manufacturing agreement with Boehringer Ingelheim

MorphoSys AG and Boehringer Ingelheim announced today the signing of a biopharmaceutical manufacturing agreement for therapeutic antibodies. The agreement covers the process development and manufacturing of additional clinical material for MorphoSys's proprietary MOR208 program and other drug candidates. MOR208, a potent monoclonal anti-CD19 antibody, is in development for the treatment of chronic lymphocytic leukemia and potentially other B-cell malignancies. The program is currently being evaluated in a phase 1 clinical trial in the USA by MorphoSys's partner Xencor Inc.

16 Mar 2011

Study: Dried plums more safe, effective than psyllium to treat constipation

Given their palatability, tolerability and availability, dried plums should be considered the initial approach to the management of mild to moderate constipation in the general population, according to results of a randomized clinical trial recently published in Alimentary Pharmacology and Therapeutics.

16 Mar 2011

Shanghai ChemPartner signs outsource research service agreement with Shenogen Pharma

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that its wholly-owned contract research subsidiary, Shanghai ChemPartner, has signed an outsource research service agreement with Shenogen Pharma Group to develop therapeutic monoclonal antibodies targeting the ER-alpha 36 receptor for cancer treatment.

16 Mar 2011

Montreal Heart Institute and Cerenis commence CER-001 Phase 2 study in acute coronary syndrome

The Montreal Heart Institute today announced the start of the Phase 2 CHI-SQUARE (Can HDL Infusions Significantly QUicken Atherosclerosis REgression?) study of CER-001 in patients with acute coronary syndrome (ACS), in collaboration with Cerenis Therapeutics, a biopharmaceutical company developing novel high-density lipoprotein (HDL) therapies to treat cardiovascular and metabolic diseases.

16 Mar 2011

Global settlement agreement reached in Tuschl patents litigation

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced the signing of a global settlement agreement among Alnylam, Max Planck Society ("Max Planck"), the Whitehead Institute for Biomedical Research ("Whitehead") and the University of Massachusetts ("UMass") resolving their ongoing litigation regarding the Tuschl patents.

16 Mar 2011

AstraZeneca commences NKTR-118 Phase III clinical programme for opioid-induced constipation

AstraZeneca today announced enrolment of the first patient in the Phase III clinical programme for NKTR-118, an oral peripherally-acting opioid antagonist being investigated for the treatment of opioid-induced constipation (OIC).

16 Mar 2011

Unigene initiates oral PTH Phase 2 study in postmenopausal women with osteoporosis

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today the dosing of the first subject in a Phase 2 study with an experimental oral parathyroid hormone analog for the treatment of osteoporosis in postmenopausal women.

16 Mar 2011

Enzo Life Sciences introduces ELISA system to detect SMN protein

Enzo Biochem, Inc. and the Spinal Muscular Atrophy Foundation today announced that Enzo's wholly owned subsidiary, Enzo Life Sciences Inc., has launched a unique immunoassay system which can be used for the identification and detection of Survival Motor Neuron protein.

16 Mar 2011

Apeiron in antitumor substances deal with Cleveland Clinic

APEIRON Biologics AG announced that it has entered into an exclusive option to license from the Cleveland Clinic a number of novel compounds. These compounds are currently in development at Cleveland Clinic as drug candidates for treatment of various cancers, designed to fight cancer based on stimulation of the immune system. In preclinical models, they have shown anti-cancer activity and a favourable toxicity profile as orally available agents.

15 Mar 2011

Researchers receive NIH grant to study effects of BBTW treatment in patients with MS

Motion Therapeutics, Inc., the leading provider of noninvasive therapeutic solutions for balance and mobility disorders, today announced that researchers at Samuel Merritt University and San Francisco State received a NIH Recovery Act Grant to study the effects of wearing a strategically weighted vest to improve gait and mobility in people with MS.

15 Mar 2011

Chelsea uses PHT's LogPad, SitePad Tablet for clinical study to treat Parkinson's patients with NOH

PHT Corporation announced that Chelsea Therapeutics is using PHT's LogPad System and SitePad Tablet for its ongoing clinical study in Parkinson's disease patients with symptomatic neurogenic orthostatic hypotension.

15 Mar 2011

Therapeutics News and Research

Alnylam to defend against Tekmira complaint

Scientists receive £5million EU grant to identify gene targets for kidney cancer treatment

ACT initiates enrollment in TEMPASURE cardiac ablation catheter CE Mark clinical trial

Astellas to acquire all Maxygen's equity interests in Perseid for $76.0 million

Inovio signs agreement with OncoSec to sell non-DNA cancer vaccine technology

PsiOxus commences MT-102 Phase II study for treatment of cancer- and age-related wasting

Researchers update 'Hallmarks of Cancer' seminal review

HGSI, FivePrime enter agreement to develop, commercialize FP-1039 for multiple cancers

Pharmaron signs agreement to provide Isis with nucleoside phosphoramidites up to 100 kg

MorphoSys inks manufacturing agreement with Boehringer Ingelheim

Study: Dried plums more safe, effective than psyllium to treat constipation

Shanghai ChemPartner signs outsource research service agreement with Shenogen Pharma

Montreal Heart Institute and Cerenis commence CER-001 Phase 2 study in acute coronary syndrome

Global settlement agreement reached in Tuschl patents litigation

AstraZeneca commences NKTR-118 Phase III clinical programme for opioid-induced constipation

Unigene initiates oral PTH Phase 2 study in postmenopausal women with osteoporosis

Enzo Life Sciences introduces ELISA system to detect SMN protein

Apeiron in antitumor substances deal with Cleveland Clinic

Researchers receive NIH grant to study effects of BBTW treatment in patients with MS

Chelsea uses PHT's LogPad, SitePad Tablet for clinical study to treat Parkinson's patients with NOH

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News